<unk>  is a vaccine used to prevent<unk> . Effectiveness begins about two weeks after a single dose and around 95% of people become immune. Countries with high rates of immunization no longer see cases of<unk>  or congenital<unk>  syndrome. When there is a low level of childhood immunization in a population it is possible for rates of congenital<unk>  to increase as more women make it to child-bearing age without either vaccination or exposure to the disease. Therefore, it is important for more than 80% of people to be vaccinated. By introducing<unk>  containing vaccines,<unk>  has been eradicated in 81 nations, as of mid-2020. The World Health Organization (WHO) recommends that the<unk>  be included in routine vaccinations. If not all people are immunized then at least women of childbearing age should be immunized. It should not be given to those who are pregnant or those with very poor immune function. While one dose is often all that is required for lifelong protection, often two doses are given. Side effects are generally mild. They may include fever, rash, and pain and redness at the site of injection. Joint pain may be reported at between one and three weeks following vaccination in women. Severe allergies are rare. The<unk>  is a live attenuated vaccine. It is available either by itself or in combination with other vaccines. Combinations include with measles (MR vaccine), measles and mumps vaccine (MMR vaccine) and measles, mumps and varicella vaccine (MMRV vaccine). A<unk>  was first licensed in 1969. It is on the World Health Organization's List of Essential Medicines. , more than 173 countries included it in their routine vaccinations.
Rubella vaccine
Polio vaccine
Typhus vaccine
MMR vaccine
MMRV vaccine
Measles vaccine
Tetanus vaccine
Typhoid vaccine